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INTRODUCTION
DIABETES OR IMPAIRED GLUCOSE TOLERANCE affects 20million individuals in the United States, and the number
is increasing by 5% per year. Diabetes-specific microvascular
complications will eventually affect nearly all individuals
with diabetes. Diabetic retinopathy is the most common
cause of adult blindness in the United States. Ninety percent
of patients have evidence of retinopathy after 15 years of dia-
betes with ~25,000 new cases of blindness per year (25). Dia-
betes is the leading cause of renal failure in the United States,
accounting for 40% of new cases each year (69). Greater than
half of all patients with diabetes develop neuropathy, making
diabetic neuropathy the most common cause of nontraumatic
amputations and autonomic failure (23, 83). In his or her life-
time, a diabetic patient with neuropathy has a 15% chance to
undergo one or more amputations (22).
Except for improved glycemic control, no specific thera-
pies are available to prevent or delay the development or pro-
gression of diabetic microvascular complications (68). Ani-
mal and in vitro experiments implicate a number of enzy-
matic and nonenzymatic pathways of glucose metabolism in
the initiation and progression of complications (72). These
include: (a) increased polyol pathway activity leading to sor-
bitol and fructose accumulation, NAD(P)-redox imbalances,
and changes in signal transduction; (b) nonenzymatic glyca-
tion of proteins yielding “advanced glycation end-products”
(AGEs); (c) activation of protein kinase C (PKC), initiating a
cascade of stress responses; (d) increased hexosamine path-
way flux; and (e) increased escape of superoxide from the
electron transfer chain through mitochondrial stress (6, 10,
72, 81, 86). Although specific inhibitors of each pathway
block one or more diabetic microvascular complications, only
recently has a link been established among the pathways that
provides a unified mechanism of tissue damage. Each path-
way is directly or indirectly associated with increased produc-
tion of reactive oxygen species (ROS) and the development of
oxidative stress.
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ABSTRACT
The concept that oxidative stress is a key mediator of nerve injury in diabetes has led us to design therapies
that target oxidative stress mechanisms. Using an in vitro model of glucose-treated dorsal root ganglion
(DRG) neurons in culture, we can examine both free radical generation, using fluorimetric probes for reactive
oxygen species, and cell death via the TUNEL assay. The cell culture system is scaled down to a 96-well plate
format, and so is well suited to high-throughput screening. In the present study, we test the ability of three
drugs, nicotinamide, allopurinol, and -lipoic acid, alone and in combination to prevent DRG neuron oxida-
tive stress and cell death. This combination of drugs is currently in clinical trial in type 1 diabetic patients. We
demonstrate independent effects on oxidative stress and neuronal survival for the three drugs, and neuronal
protection using the three drugs in combination. The data strengthen the rationale for the current clinical
trial. In addition, we describe an effective tool for rapid preclinical testing of novel therapies against diabetic
neuropathy. Antioxid. Redox Signal. 7, 1494–1506.
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Our work has focused on one specific microvascular com-
plication, diabetic neuropathy, and supports the concept that
glucose-mediated oxidative stress underlies the development
of this complication (52, 58, 65, 70, 80). In diabetic rats,
there is evidence of mitochondrial dysfunction and ROS ac-
cumulation in dorsal root ganglion (DRG) neurons and
Schwann cells, followed by caspase cleavage and the ultra-
structural hallmarks of apoptosis (18, 31, 32, 64, 66). In vitro,
DRG neurons exposed to increased concentrations of glucose
accumulate ROS with subsequent caspase cleavage and pro-
grammed cell death (15, 65, 66, 81). These data parallel re-
cent studies in man, where patients with type 1 diabetes and
high serum levels of ROS markers had more severe peripheral
and autonomic neuropathy (60). Collectively, these results led
us to investigate the potential beneficial effects on neuronal
survival of blocking glucose-mediated ROS accumulation.
We reasoned that compounds that blocked ROS formation
and programmed cell death in glucose-treated neurons could
provide new treatment options for patients with diabetic neu-
ropathy. In the current study, we report that the drugs in a cur-
rent triple therapy clinical trial in man, allopurinol, -lipoic
acid, and nicotinamide, individually rescue DRG neurons
from glucose-induced ROS and cell injury, but with different
potencies. In addition, these drugs in combination prevent
glucose-mediated DRG neuron injury.
MATERIALS AND METHODS
DRG culture model of hyperglycemia
DRG are harvested from embryonic day 15 Sprague–
Dawley rats, dissociated in 1% trypsin, then cultured on tis-
sue culture plates in growth medium. Plates are coated with
rat tail type 1 collagen (Sigma, St Louis, MO, U.S.A.) prior to
applying DRG neurons as follows. Immediately prior to use,
collagen is dissolved in sterile 1 M acetic acid to 10 mg/ml,
then diluted in sterile distilled water to 1 mg/ml, spread in a
thin layer on the culture plate, and allowed to air dry in a lam-
inar flow hood. All culture reagents are from GIBCO (Grand
Island, NY, U.S.A.) unless stated otherwise. Growth medium
is prepared using Neurobasal medium supplemented with 1
 B-27 additives, 50 ng/ml nerve growth factor (NGF; Har-
lan Bioscience, Indianapolis, IN, U.S.A.), 40 µM fluo-
rodeoxyuridine (FUDR; Sigma), and 1,000 U/ml penicillin/
streptomycin/neomycin solution. Initial plating medium con-
tains 2 µM glutamine. DRG neurons are refed after 24 h in
fresh medium containing all additives except glutamine. On
day 2, cells are rinsed, then refed using treatment medium
(Neurobasal medium containing 4 ng/ml selenium, 4 ng/ml
hydrocortisone, 0.01 mg/ml transferrin, 3 ng/ml -estradiol,
50 ng/ml NGF, 40 µM FUDR, and 1,000 U/ml penicillin/
streptomycin/neomycin). Experiments are performed on DRG
neurons on the third day in culture in the absence of B-27 ad-
ditives. Neurobasal medium contains a basal 25 mM glucose
that is essential for DRG neuron culture (18, 31, 32, 64–66).
A decrease to 5 mM glucose leads to increased DRG neuron
death, whereas increasing the glucose concentration above 35
mM induces hyperglycemic stress, ROS, and cell injury (65).
To produce a hyperglycemic insult, 20 mM additional glucose
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(yielding a total 45 mM glucose) is added to the medium for
the period specified in individual experiments. Medium glu-
cose concentrations do not significantly decrease during the
treatment periods as determined by mass spectrometry.
Fragmentation of genomic DNA
TdT-mediated dUTP-biotin nick-end labeling (TUNEL)
staining is used to detect programmed cell death in DRG neu-
rons. DRG neurons are fixed in 4% paraformaldehyde prior
to staining. Samples are labeled with digoxygenin-dUTP and
then stained with horseradish peroxidase-conjugated anti-
digoxygenin antibody using a kit according to the manufac-
turer’s instructions (Intergen, Gaithersburg, MD, U.S.A.).
Cleavage of caspase-3
To detect caspase-3 staining, the CaspaTag technique (In-
tergen) is used. This kit contains a cell-permeable, fluores-
cence-tagged caspase-3 substrate that binds irreversibly to
the active site of caspase-3. Thus, DRG neurons containing
active caspase-3 are rapidly identified by microscopy.
Reagents were obtained in the kit form and used according to
the manufacturer’s instructions. The CaspaTag caspase-3 sub-
strate is applied to the cultures for the final 30 min of an
assay incubation period, and then cells are immediately rinsed
and fixed. The nuclear chromatin is counterstained with
1 µg/ml bisbenzamide in phosphate-buffered saline. Neurons
are considered to have active caspase-3 if staining can be
clearly localized to the neuronal cytosol using fluorescence
microscopy.
Measurement of ROS
The cell-permeant dihydroethidium (DHE), which is oxi-
dized relatively specifically by superoxide (87), and 2,7-
dichlorodihydrofluorescein diacetate (DCFDA), which is oxi-
dized primarily by hydrogen peroxide (H2O2) (88) (Molecular
Probes, Eugene, OR, U.S.A.), are used to assess real-time
ROS formation in DRG neurons. Reduced DHE emits blue
fluorescence. Exposure to ROS, superoxide in particular,
causes oxidation to ethidium that displays red fluorescence.
Stock DHE is dissolved at a concentration of 10 mg/ml in di-
methyl sulfoxide (DMSO), diluted to 150 µM in HEPES-
buffered saline solution (HBSS; 10 mM HEPES, pH 7.4, 150
mM NaCl, 5 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2) immedi-
ately prior to use, then added directly to the culture medium
at a 1:50 dilution, giving a final concentration of 3 µM. The
DHE solution is applied to DRG neurons for the final 15 min
of an experiment, and then neurons are rinsed once rapidly in
HBSS and immediately placed in a fluorescence plate reader
(Fluroskan Ascent II, Labsystems, Helsinki, Finland). For
each sample, the ratio of red (518 nm excitation, 605 nm emis-
sion) over blue (485 nm excitation, 520 nm emission) fluores-
cence is determined with 1-s integration for each reading.
Reduced DCFDA is nonfluorescent, but following oxida-
tion, generally by H2O2, green fluorescent 2,7-dichlorofluo-
rescein (DCF) is generated. Stock DCFDA is dissolved in
DMSO initially at 5 mg/ml, then diluted in HBSS to 17
µg/ml. Similar to the DHE assay, the diluted DCFDA is ap-
plied to the culture medium at 1:50 dilution 15 min prior to
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the end of a treatment period; then after 15 min, the cells are
rinsed in HBSS and examined in the fluorescent plate reader.
DCF fluorescence is assessed with 485 nm excitation and
520 nm emission with 1-s integration.
Real-time lipid peroxidation
MitoFOX was supplied by Molecular Probes, Inc. This
probe is under development and is aimed at the specific de-
tection of mitochondrial lipid peroxidation. It is not clear at
present whether the probe is detecting specific lipid peroxi-
dation or general oxidative mechanisms. The probe was dis-
solved in DMSO to produce a 2 mM stock solution, then di-
luted to 100 µM working solution using HBSS. The probe was
added using two different experimental paradigms where
DRG neurons were either preloaded with MitoFOX or labeled
for the final 15 min of the incubation period. In each case, a
final concentration of 250 nM MitoFOX was applied to the
DRG neurons. At the end of the experimental period, DRG
neurons were rinsed in HBSS, then fixed in paraformalde-
hyde, mounted in Prolong Antifade (Molecular Probes), and
examined by fluorescence microscopy.
Statistical analysis
All experimental samples are assayed on three separate
occasions with two or three replicates in each assay. For de-
termination of percent positive in assays of cell death, at least
10 fields, each containing at least 10 neurons, are counted per
replicate assay. The total numbers of cells in each field are
compared between experimental and control conditions to
confirm that the numbers are equivalent. This is important to
consider, because if dying cells detach from the dish, the data
are skewed. The mean and standard error for the three repeats
are calculated. Statistical significance is determined using
ANOVA with 95% confidence intervals.
RESULTS
A cell culture drug-screening paradigm
Simulation of diabetes-induced DRG neuron stress in cell
culture permits the screening for DRG neuron-protective
compounds with potential to prevent diabetic neuropathy.
Figure 1A illustrates the experimental paradigm used for
high-throughput screening with DNA fragmentation as the
end-point assay.
Figure 1B shows representative TUNEL staining in untreated
control DRG neurons and glucose-treated (20 mM added glu-
cose for 24 h) DRG neurons. Currently, the TUNEL assay rep-
resents a more quantifiable parameter for the measurement of
DRG neuron injury. In particular, the time course of TUNEL
staining in the DRG neurons increases with duration of injury
up to 8 h following the application of 20 mM glucose, but does
not decrease with longer exposures (unpublished observations).
This is important as other markers, such as caspase-3 staining
and MitoFOX labeling, decrease following a peak in staining. A
more intense insult may produce an earlier peak in staining, and
give a false positive result for a decrease in staining at the se-
lected time point, illustrated in Fig. 1C.
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A novel assay to examine 
peroxidation in mitochondria
An additional technique under appraisal is the detection
of mitochondrial lipid peroxidation using a fluorimetric
probe, MitoFOX (Molecular Probes). As oxidative stress is
an early contributor to glucose-mediated oxidative stress,
therapeutics targeted specifically to this mechanism may be
rapidly and sensitively assessed through this method. Typi-
cal labeling with the probe is illustrated in Fig. 2. In Fig.
2A, untreated control DRG neurons or DRG neurons ex-
posed to 20 mM added glucose for 3 h were labeled with
250 nM MitoFOX for 15 min. The probe is under develop-
ment to specifically detect mitochondrial lipid peroxidation,
although the true specificity of this probe is not yet known.
Markedly greater green fluorescence indicative of mito-
chondrial lipid peroxidation is seen in DRG neurons ex-
posed to 20 mM added glucose compared with DRG neu-
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FIG. 1. High-throughput screening in primary DRG neu-
ron cultures. (A) Schedule of culture and treatment in the
drug screening paradigm. (B) Representative images of
TUNEL-stained DRG neurons following 24-h exposure to con-
trol treatment medium or treatment medium containing 20 mM
added glucose. Black arrows indicate brown, TUNEL-positive
nuclei. Healthy nuclei stain blue with hematoxylin. (C) Sample
data to illustrate the utility of the TUNEL assay of cell death in
this system, as opposed to test systems that rely on a parameter
that increases to a peak and then declines with increased stress
or injury.
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rons in basal glucose (Fig. 2A). The lipid peroxidation ap-
pears to be localized to the mitochondria through double-
loading with Mitotracker red at a concentration of 100 nM
(Molecular Probes) that labels the mitochondria (Fig. 2B).
The overlay of red and green fluorescence demonstrates
colocalization of the probes, indicating that MitoFOX is
most likely accumulating in the mitochondria. Quantitation
of green MitoFOX labeling using a fluorescent plate reader
(Labsystems Ascent II) demonstrates a significant increase
in lipid peroxidation by 1 h following the application of 20
mM glucose that continues to increase at 3 h and then begins
to decrease by 5 h (Fig. 2C). If the specificity of this probe
for lipid peroxidation is confirmed, the sensitivity of this
technique suggests this will be a useful tool for determining
the mechanisms of oxidative injury.
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Antioxidant drugs can decrease 
glucose-induced DRG neuron injury
These screening protocols were used to assess the efficacy
of a novel combination therapy for diabetes complications
that is currently in clinical trial (www.umich.edu/~jdrf/).
FDA-approved doses of allopurinol, nicotinamide, and -
lipoic acid are being used in a 2-year double-blind placebo-
controlled study in type 1 diabetic patients with tests of dia-
betic neuropathy as the clinical end point. First, these drugs
were assessed alone for the ability to prevent glucose-induced
DRG neuron death in the high-throughput screening para-
digm (Fig. 3). The concentration ranges for these compounds
were selected using information available from their use in
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FIG. 2. Assay for lipid peroxidation using MitoFOX. Mitochondrial lipid peroxidation may be rapidly screened using the
novel probe MitoFOX. (A) DRG neurons in basal (25 mM) glucose and neurons exposed to 20 mM added (45 mM total) glucose
for 1 h were loaded with 250 nM MitoFOX for 15 min, then photographed with fluorescein isothiocyanate fluorescence filters.
(B) Images were taken after 1-h exposure to 20 mM added glucose. Lipid peroxidation (green) can be observed within 1 h and can
be localized to mitochondria using Mitotracker probe (red), with overlap of the two probes shown in yellow in the overlay.
(C) MitoFOX was added to glucose-treated DRG neurons grown in 24-well plates. The mean fluorescence per well was measured
in a fluorescence plate reader (Labsystems Ascent II) at 485 nm excitation and 520 nm emission. The mean and standard errors of
the fluorescence for three separate assays are plotted. *Fluorescence increased significantly within 1 h of application of 20 mM
glucose (p < 0.05) and increased again by 3 h.
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range of neuroprotective concentrations from 10 to 25 mM
(Fig. 3A). In this range, nicotinamide significantly de-
creases glucose-induced DRG neuron death. In contrast, al-
lopurinol alone produces only a modest decrease in TUNEL
labeling at >500 µM concentration (Fig. 3B). -Lipoic acid
is the most potent DRG neuron protective agent. At concen-
trations of >60 µM, glucose-induced DRG neuron injury is
prevented.
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Individual drugs differentially 
alter the generation of ROS
The differential potency of these compounds to protect the
DRG neurons may be linked to the ability to prevent oxida-
tive stress. To test this hypothesis, the production of ROS was
assessed in another high-throughput assay that utilizes fluori-
metric probes. To assess superoxide, DRG neurons were
loaded with DHE, and the change in fluorescence as DHE
was oxidized to ethidium was measured in a 96-well plate
reader (Fluoroskan, Labsystems). Similarly, H2O2 may be de-
termined through the oxidation of nonfluorescent DCFDA to
green fluorescent DCF in the same plate reader.
Nicotinamide alone decreases basal superoxide over a nar-
row concentration range from 7.5 to 15 mM (Fig. 4A). Lower
concentrations of nicotinamide in the range 0.5–1 mM mod-
estly decrease glucose-induced DHE oxidation, whereas
12.5 mM nicotinamide is the only concentration that signifi-
cantly decreases basal superoxide as well as decreases
glucose-induced superoxide to the level of untreated control
DRG neurons. At 20 mM nicotinamide and above, DHE oxi-
dation is increased by nicotinamide alone.
Because of the unusual profile of DHE oxidation over the
dose–response curve of nicotinamide, the effects of nicotin-
amide on the oxidation of DCFDA that is attributable to H2O2
was also assessed (Fig. 4B). Low concentrations (0.5–5 mM)
of nicotinamide induce a peak of H2O2 that decreases in the
neuroprotective range of 10–15 mM. At 20 mM nicotinamide
and higher concentrations, H2O2 is again produced by nicoti-
namide alone. In the presence of glucose, the low concentra-
tions of nicotinamide decrease glucose-induced H2O2 in a
dose-dependent-manner. At the neuroprotective concentra-
tions, DCFDA oxidation is so low it is undetectable. Above
20 mM nicotinamide, the drug no longer prevents and instead
exacerbates the production of H2O2 in the presence of 20 mM
added glucose.
Allopurinol also alters the generation of superoxide in
DRG neurons (Fig. 4C). Increasing concentrations of allo-
purinol alone slightly increase superoxide up to the 63 µM
concentration. Between 125 and 500 µM, superoxide forma-
tion markedly decreases by >50%. Low concentrations of
allopurinol do not prevent glucose-induced superoxide for-
mation, but with 16 µM allopurinol and higher, glucose-
induced superoxide decreases in a dose-dependent manner up
to 500 µM compared with glucose alone.
-Lipoic acid decreases both basal and glucose-induced
superoxide at as low as 10 µM concentration. The decrease in
superoxide is greater with increasing concentrations of -
lipoic acid up to 60 µM. Glucose-induced superoxide contin-
ues to decrease with up to 1,000 µM -lipoic acid, when DHE
oxidation is slightly lower than basal levels in untreated DRG
neurons.
Nicotinamide and -lipoic acid prevent 
H2O2-induced DRG neuron injury
Because the drugs demonstrate different capacities to alter
glucose-induced superoxide and injury in DRG neurons, we
further assessed the neuroprotective ability of these compounds
against oxidative stress injury. DRG neurons were treated





















































































FIG. 3. Effect of individual drug treatments on glucose-in-
duced DRG neuron death. Cell death, as assessed by the
TUNEL assay that is indicative but not restricted to pro-
grammed cell death pathways, was determined 24 h following
exposure to 20 mM added glucose with and without increasing
concentrations of nicotinamide (A), allopurinol (B), or a-lipoic
acid (C). The means and standard errors for three replicate as-
says are shown. *Drug concentration that significantly de-
creased DRG neuron injury compared with glucose alone (p <
0.05).












































































































FIG. 4. Effect of individual drug treatments on glucose-induced DRG neuron ROS generation. The fluorimetric probe
DHE, which is indicative of superoxide generation, was applied to DRG neurons 5 h following exposure to 20 mM added glucose
with and without increasing concentrations of each of the test drugs (A, C, and D). The probe DCFDA was also assessed in a sim-
ilar manner in a nicotinamide dose curve (B). The means and standard errors of the fluorescence for three separate assays are
shown in each panel. +Nicotinamide in the range 5–15 mM decreased glucose-induced DCF oxidation, p < 0.01. **12.5 mM
nicotinamide significantly decreased basal DHE oxidation compared with untreated control cultures. *Significant decrease in
ROS formation compared with glucose-exposed control cultures, p < 0.05.
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allopurinol (1 mM), or -lipoic acid (100 µM) prior to the ap-
plication of 1 µM H2O2. Similar to the drug-screening proto-
col, the DRG neurons were then fixed after 24 h and TUNEL-
stained. Both nicotinamide and -lipoic acid prevented
H2O2-induced DRG neuron injury, whereas allopurinol was not
protective (Fig. 5). These data suggest that allopurinol does not
effectively scavenge ROS in this experimental system.
The triple therapy drug combination prevents
glucose-induced DRG neuron injury in the cell
culture screening model
Next, combinations of the drugs were assessed. To per-
form these studies, stock solutions of the drug combination
were treated with 1,000 U/ml catalase for 1 h prior to applica-
tion to the cells. This removes H2O2 that may be generated
during the solubilization process (29, 82) and may be directly
toxic to the cultured DRG neurons. Because allopurinol dem-
onstrated the lowest ability to protect the DRG neurons, but
provided an increase in protection between 500 µM and 1,000
µM, both these concentrations were tested to determine
whether allopurinol contributed to the neuronal protection.
Combination of the three drugs provides potent protection
against glucose-induced ROS and DRG neuron death (Fig. 6).
The drug combination alone does not alter basal superoxide
(Fig. 6A) or H2O2 (Fig. 6B). One exception is that the combi-
nation of 1 mM allopurinol with 12.5 mM nicotinamide and
100 µM -lipoic acid modestly decreases basal levels of su-
peroxide. In the presence of glucose, the drug combination
decreases, but does not fully prevent the increase in superox-
ide, with 1 µM allopurinol providing a significant improve-
ment over 0.5 µM allopurinol (Fig. 6A).
1500 VINCENT ET AL.
The drug combination completely prevents glucose-in-
duced DRG neuron injury, as assessed by both the cleavage of
caspase-3 and TUNEL staining (Fig. 6C).
DISCUSSION
Accumulating data suggest that glucose-mediated oxida-
tive stress underlies the development of diabetic neuropathy
(52, 58, 65, 70). One rational therapeutic approach to the
treatment of diabetic neuropathy is to block oxidative stress
(80). The current study tested the feasibility of a therapeutic
strategy, which will prevent oxidative damage by three differ-
ent mechanisms. We propose to attenuate the development of
oxidative stress by using the xanthine oxidase inhibitor, al-
lopurinol, quench oxidative stress by the use of the chain-
breaking antioxidant -lipoic acid, and prevent the down-
stream consequences of oxidative stress using the
poly(ADP-ribose) synthase (PARS) inhibitor nicotinamide.
Each of these compounds was tested alone and in combina-
tion for the ability to prevent oxidative stress and DRG neu-
ron death.
Allopurinol alone modestly increases superoxide forma-
tion in a dose-dependent manner and only modestly prevents
glucose-induced DRG neuron death at high concentrations.
Yet, in the combination therapy, a higher concentration of al-
lopurinol (1,000 µM) provides increased survival compared
with a lower (500 µM) concentration. The data suggest that
allopurinol does provide neuronal protection, but requires ad-
ditional antioxidants to observe the effect in a cell culture
system. The lack of effect in the experiments using allopuri-
nol alone probably relates to the difficulty of solubilizing the
compound and the probable generation of H2O2 during solu-
bilization (29). This would explain why we observe an added
benefit of allopurinol in the presence of -lipoic acid.
Taken together, the data do not provide compelling evi-
dence for the use of allopurinol for direct neuronal protec-
tion. These data increase our confidence in the drug screen-
ing technique to identify compounds that specifically
promote DRG neuron survival. Yet allopurinol promotes en-
dothelial function in diabetes (5), and so remains a beneficial
component of the triple therapy. Perhaps a similar screen
using cultured vascular endothelial cells would demonstrate
the protective ability of this compound. Allopurinol is a xan-
thine oxidase inhibitor. Xanthine oxidase catalyzes conver-
sion of hypoxanthine to xanthine, and xanthine to uric acid
and functions as both a scavenger and inhibitor of oxygen
free radical production (i.e., superoxide, H2O2, and hydroxyl
radicals) (24). In human aortic endothelial cells, xanthine ox-
idase is a major source of free radicals (93), and allopurinol
treatment improves endothelial dysfunction (5). Allopurinol
has been most extensively evaluated in the prevention of ox-
idative stress-induced myocardial injury. For example, clini-
cal studies have demonstrated that allopurinol confers neuro-
cardiac protection, improves myocardial function, and
decreases arrhythmias following ischemia–reperfusion injury
(11, 16, 17, 28, 30, 63, 74). Allopurinol can also preserve
high-energy phosphate levels (56) in ischemic myocardium,
to decrease muscle creatinine kinase release following car-





























FIG. 5. Effect of individual drugs on H2O2-induced DRG
neuron injury. Each of the drugs at a concentration that pre-
vented glucose-induced DRG neuron injury was tested for the
ability to prevent TUNEL staining induced by 1 µM H2O2. The
drug concentrations were as follows: nicotinamide, 12.5 mM;
allopurinol, 1 mM; -lipoic acid, 100 µM. The same treatment
schedule as the drug screen illustrated in Fig. 1 was used, with
the exception that the -lipoic acid-treated cultures were rinsed
prior to the application of H2O2 to remove the catalase that was
originally used to treat the -lipoic acid stock solution. *-
Lipoic acid and nicotinamide significantly prevented H2O2-in-
duced DRG neuron injury, p < 0.01.
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els of myocardial ischemia (1, 3, 47). These effects may be
mediated by decreasing oxidative damage. Allopurinol atten-
uates brain damage in neonatal rats via peri-injury adminis-
tration, and decreases cerebral cortical free radical produc-
tion in hypoxic infant piglets (16, 85). Allopurinol prevents
accumulation of the lipid peroxidation product malondialde-
hyde (MDA), improves cerebral perfusion, and maintains
cerebral electrical activity in asphyxiated human neonates
(16, 79).
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A recent clinical trial (8) examined the effects of
300 mg/day allopurinol on endothelial function and oxidative
stress in type 2 diabetic patients. Allopurinol or placebo was
administered for 1 month and the effects on forearm blood
flow responses determined. Allopurinol, but not placebo, in-
creased the endothelium-dependent mean blood flow re-
sponse to acetylcholine by 30% and decreased systemic lev-
els of MDA. These data are consistent with our hypothesis



















































































FIG. 6. Effect of the triple drug combination on ROS generation and cell injury. The combinations of allopurinol [0.5 mM
(A0.5) or 1.0 mM (A1)], nicotinamide [12.5 mM (N)], and -lipoic acid [100 µM (L)] were applied to DRG neurons with or with-
out the application of 20 mM glucose (G). Generation of superoxide (A) was determined after 5 h. Development of caspase-3 ac-
tivation was determined after 5 h (B), or TUNEL staining was determined after 24 h (C). In each case, application of the triple
combination of drugs did not alter DHE oxidation or DRG neuron injury in the absence of added glucose (compare drug combi-
nation with Control). In contrast, the drug combination significantly decreased each of these parameters in the presence of 20 mM
added glucose: *p < 0.01; +p < 0.05.
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tributes to endothelial and neuronal dysfunction. In the cul-
ture system, allopurinol does not prevent H2O2-induced DRG
neuron injury, further demonstrating that this compound
functions through the prevention of ROS formation, such as
through inhibition of xanthine oxidase, rather than through
ROS scavenging and antioxidant activity.
-Lipoic acid potently protects DRG neurons in the cell
culture system. This compound decreases glucose-induced
free radical generation and cell death in a dose-dependent
manner that strongly supports our contention that oxidative
stress is a significant mediator of glucose-induced neuronal
injury. -Lipoic acid is an endogenous free radical scavenger
(46) and metal chelator that also activates glucose uptake and
the pyruvate dehydrogenase complex, and serves as a meta-
bolic substrate for the E3 pyruvate dehydrogenase compo-
nent. -Lipoic acid is reduced to dihydrolipoate, which com-
bines free radical (hydroxyl, superoxide, peroxyl, singlet
oxygen)-scavenging and metal-chelating properties with the
ability to regenerate concentrations of nonenzymatic and en-
zymatic antioxidants (39, 49). In preclinical studies, -lipoic
acid administration improved nerve function in diabetic rats
(9, 46, 71). In streptozotocin-induced diabetes in rats, -
lipoic acid significantly improves or normalizes deficits in
digital sensory nerve conduction velocity, endoneurial nutri-
tive nerve blood flow, mitochondrial and cytoplasmic
NAD+/NADH ratios, Na+,K+-ATPase activity, levels of total
and reduced glutathione, and the activities of superoxide dis-
mutase, catalase, and cytochrome b5 reductase (71). Taurine,
an important endogenous metal chelator with antioxidant
(4, 49, 55, 76) and anti-PKC effects (38), is also depleted in
nerve by streptozotocin-induced diabetes and restored by -
lipoic acid (71). -Lipoic acid corrects deficits in NGF-
dependent neuropeptide-Y and substance-P expression in pe-
ripheral nerve and spinal cord in streptozotocin-induced
diabetic rats (26).
-Lipoic acid has been extensively evaluated in man, in-
cluding seven phase I clinical studies (which included type 1
diabetic patients), three phase II clinical studies in type 2 dia-
betic subjects, and three phase III clinical studies. In a dose-
finding clinical trial [Alpha-Lipoic Acid in Diabetic Neu-
ropathy (ALADIN) Study], treatment with intravenous
-lipoic acid for 3 weeks ameliorated major neuropathic
symptoms (i.e., pain and paraesthesias) in type 2 diabetic
subjects with polyneuropathy (89). In another study
[Deutsche Kardiale Autonome Neuropathie (DEKAN)
Study], an improvement of heart rate variability was found
after 4 months of oral treatment with -lipoic acid
(800 mg/day) in type 2 diabetic patients with diabetic auto-
nomic neuropathy (90). In the ALADIN III Study (91), 509
subjects with type 2 diabetes and symptomatic diabetic neu-
ropathy were administered sequential treatment with 600
mg/day -lipoic acid given intravenously for 3 weeks fol-
lowed by 600 mg three times a day for 6 months. The total
neuropathy symptom score was significantly better at early
time points in the -lipoic acid-treated group, and neuro-
pathic deficits were consistently improved throughout the
study. Adverse events were not different between groups.
Therefore, extensive clinical trial data indicate that -lipoic
acid is effective in ameliorating both neuropathic symptoms
and deficits of cardiovascular autonomic function. Moreover,
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-lipoic acid is safe and, at the dose of 600 mg three times a
day, without significant adverse effects.
Nicotinamide demonstrates potent neuronal protection in
the DRG neuron culture system, but over a narrow concentra-
tion range. The biphasic nature of nicotinamide-mediated
protection suggests that more than one cellular mechanism is
activated in DRG neurons by this compound. The best de-
scribed mechanism of nicotinamide is as an inhibitor of
poly(ADP-ribosylation), i.e., the transfer of the ADP-ribose
moieties from NAD to nuclear proteins by the enzyme PARS.
Activation of PARS has emerged as an important potential
mediator of glucose-induced oxidative damage (54). PARS is
expressed in all cell types and is activated by DNA single-
strand breakage (2), resulting from hydroxyl and superoxide
anion radicals and peroxynitrite (14, 43). PARS activation is
associated with energy depletion (75) and increased oxidative
stress (92). PARS activation contributes to apoptosis (48),
and PARS-knockout mice demonstrate protection from apop-
tosis (67). PARS activation is implicated as a mediator of
many pathological conditions associated with oxidative
stress, such as myocardial ischemia, cerebrovascular disease,
renal ischemia–reperfusion (73), and pancreatic -cell failure
(13, 19, 20, 36, 37, 41, 45, 77, 78). Our present data suggest
that at low concentrations nicotinamide increases H2O2 gen-
eration and modestly prevents superoxide generation. Once a
concentration is reached that is known to inhibit PARS,
nicotinamide prevents glucose-mediated injury. At higher
concentrations, nicotinamide increases oxidative stress and
so may override the protective effect of PARS inhibition.
In addition to PARS inhibition, nicotinamide is known to
modulate immune cell function and survival via inhibition of
ADP-ribosyl transferring enzymes (7, 33, 34, 40). Nicotin-
amide decreases production of tumor necrosis factor- and
interleukin-12 in cultures of whole blood from prediabetic
and diabetic subjects (35). These effects have been proposed
to confer protection to pancreatic  cells (57). Indeed, nico-
tinamide has been used in human clinical trials at high doses
for many years, most recently for studying prevention of type
1 diabetes mellitus in high-risk patients through  cell preser-
vation (13, 19, 20, 36, 37, 41, 45, 77, 78). Nicotinamide has
been given to subjects with new-onset type 1 diabetes, at
doses ranging from 200 mg to 3.5 g per day for 12 months
with very low incidences of side effects or toxicity (13, 33,
37, 45, 61, 62, 77, 78, 84), for periods of 4 months to 4 years
(19, 20, 33, 36). The European Nicotinamide Diabetes Inter-
vention Trial (ENDIT) is currently monitoring use of nicotin-
amide (1.2 g/m2, maximum 3 g/day) in 276 individuals with
high risk for developing type 1 diabetes mellitus (33, 57).
Taken together, the data suggest that nicotinamide may not
scavenge ROS in the cell culture system, but at specific con-
centrations that activate PARS it is protective. The increase in
ROS generation at high concentrations of nicotinamide, seen
in this and other systems (92), is detrimental to the DRG neu-
rons in culture and can increase injury in the presence of
hyperglycemia.
The concept that increased ROS and oxidative stress oc-
cupy a central position in the pathogenesis of diabetic com-
plications led us to identify new therapies aimed at different
arms of the oxidative stress pathway (80). Individually, these
therapies produce short-term benefits on surrogate measures
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of diabetic complications in cell culture and animal models of
diabetic complications (50, 51–53, 59). Clinical efficacy in
type 1 patients is therapeutically more challenging than ani-
mal experiments, in part because hyperglycemia is more
chronic and tissue damage more advanced in patients with di-
abetic clinical complications. Because we and others have
now identified multiple metabolic perturbations that act syn-
ergistically to produce oxidative stress in complications-
prone tissues, we contend that combination therapy targeting
the different aspects of oxidative stress will be particularly ef-
ficacious (21). The current trial uses nicotinamide, -lipoic
acid, and allopurinol. In vitro screening of these compounds
supports our choices. These compounds clearly function
through different mechanisms to decrease oxidative stress,
and together provide synergistic therapeutic benefit. This
technique will allow further rapid screening of many more
compounds in different combinations in order to efficiently
design new clinical trials.
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